Radiological correlates and clinical implications of the paradoxical lung function response to β2 agonists: An observational study

Surya P. Bhatt, James M. Wells, Victor Kim, Gerard J. Criner, Craig P. Hersh, Megan Hardin, William C. Bailey, Hrudaya Nath, Young il Kim, Marilyn G. Foreman, Douglas S. Stinson, Carla G. Wilson, Stephen I. Rennard, Edwin K. Silverman, Barry J. Make, Mark T. Dransfield

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Background: Bronchodilator response has been noted in a significant proportion of patients with chronic obstructive pulmonary disease (COPD). However, there are also reports of a paradoxical response to β2 agonists resulting in bronchoconstriction. Asymptomatic bronchoconstriction is likely to be far more common than is symptomatic bronchoconstriction with β2 agonists, but no systematic studies have been done. We assessed the prevalence of paradoxical response in current and former smokers with and without COPD, and its radiological correlates and clinical implications. Methods: Non-Hispanic white and African-American patients (aged 45-80 years) from a large multicentre study COPDGene were classified into two groups on the basis of a paradoxical response, defined as at least a 12% and 200 mL reduction in forced expiratory volume in 1 sec (FEV1) or forced vital capacity (FVC), or both, after administration of a shortacting β2 agonist (180 μg salbutamol). Findings: Patients were recruited from January, 2008, to June, 2011. 9986 (96%) of 10 364 patients enrolled in the COPDGene study were included in the analysis population (mean age 59·6 years [SD 9·0]). Paradoxical response was noted in 453 (5%) of 9986 patients and the frequency was similar in patients with COPD (198 [4%] of 4439) and smokers without airflow obstruction (255 [5%] of 5547). Compared with white patients, a paradoxical response was twice as common in African-American patients (227 [7%] of 3282 vs 226 [3%] of 6704; p<0·0001). In the multivariate analyses, African-American ethnic origin (adjusted odds ratio 1·89, 95% CI 1·50-2·39; p<0·0001), less emphysema (0·96, 0·92-0·99; p=0·023), and increased wall-area percentage of the segmental airways (1·04, 1·01-1·08; p=0·023) were independently associated with a paradoxical response. A paradoxical response was independently associated with worse dyspnoea (adjusted β for Modified Medical Research Council Dyspnoea Scale 0·12 [95% CI 0·00 to 0·24]; p=0·05), lower 6 min walk distance (-45·8 [-78·5 to -13·2]; p=0·006), higher Body Mass Index, Airflow Obstruction, Dyspnea, and Exercise Capacity (BODE) index (0·31 [0·19 to 0·43]; p<0·0001), and a greater frequency of severe exacerbations (increased by a factor of 1·35, 1·00-1·81; p=0·048). Interpretation: Paradoxical response to β2 agonists is associated with respiratory morbidity and is more common in African-Americans. These findings might have implications for the use of β2agonists in some patients. Funding: National Institutes of Health.

Original languageEnglish (US)
Pages (from-to)911-918
Number of pages8
JournalThe Lancet Respiratory Medicine
Volume2
Issue number11
DOIs
StatePublished - Nov 1 2014

Fingerprint

Observational Studies
Lung
African Americans
Bronchoconstriction
Dyspnea
Chronic Obstructive Pulmonary Disease
Albuterol
Bronchodilator Agents
Vital Capacity
Emphysema
Forced Expiratory Volume
National Institutes of Health (U.S.)
Multicenter Studies
Biomedical Research
Body Mass Index
Multivariate Analysis
Odds Ratio
Exercise
Morbidity
Population

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Radiological correlates and clinical implications of the paradoxical lung function response to β2 agonists : An observational study. / Bhatt, Surya P.; Wells, James M.; Kim, Victor; Criner, Gerard J.; Hersh, Craig P.; Hardin, Megan; Bailey, William C.; Nath, Hrudaya; Kim, Young il; Foreman, Marilyn G.; Stinson, Douglas S.; Wilson, Carla G.; Rennard, Stephen I.; Silverman, Edwin K.; Make, Barry J.; Dransfield, Mark T.

In: The Lancet Respiratory Medicine, Vol. 2, No. 11, 01.11.2014, p. 911-918.

Research output: Contribution to journalArticle

Bhatt, SP, Wells, JM, Kim, V, Criner, GJ, Hersh, CP, Hardin, M, Bailey, WC, Nath, H, Kim, YI, Foreman, MG, Stinson, DS, Wilson, CG, Rennard, SI, Silverman, EK, Make, BJ & Dransfield, MT 2014, 'Radiological correlates and clinical implications of the paradoxical lung function response to β2 agonists: An observational study', The Lancet Respiratory Medicine, vol. 2, no. 11, pp. 911-918. https://doi.org/10.1016/S2213-2600(14)70185-7
Bhatt, Surya P. ; Wells, James M. ; Kim, Victor ; Criner, Gerard J. ; Hersh, Craig P. ; Hardin, Megan ; Bailey, William C. ; Nath, Hrudaya ; Kim, Young il ; Foreman, Marilyn G. ; Stinson, Douglas S. ; Wilson, Carla G. ; Rennard, Stephen I. ; Silverman, Edwin K. ; Make, Barry J. ; Dransfield, Mark T. / Radiological correlates and clinical implications of the paradoxical lung function response to β2 agonists : An observational study. In: The Lancet Respiratory Medicine. 2014 ; Vol. 2, No. 11. pp. 911-918.
@article{7cea17264ad840c885c601001969f72c,
title = "Radiological correlates and clinical implications of the paradoxical lung function response to β2 agonists: An observational study",
abstract = "Background: Bronchodilator response has been noted in a significant proportion of patients with chronic obstructive pulmonary disease (COPD). However, there are also reports of a paradoxical response to β2 agonists resulting in bronchoconstriction. Asymptomatic bronchoconstriction is likely to be far more common than is symptomatic bronchoconstriction with β2 agonists, but no systematic studies have been done. We assessed the prevalence of paradoxical response in current and former smokers with and without COPD, and its radiological correlates and clinical implications. Methods: Non-Hispanic white and African-American patients (aged 45-80 years) from a large multicentre study COPDGene were classified into two groups on the basis of a paradoxical response, defined as at least a 12{\%} and 200 mL reduction in forced expiratory volume in 1 sec (FEV1) or forced vital capacity (FVC), or both, after administration of a shortacting β2 agonist (180 μg salbutamol). Findings: Patients were recruited from January, 2008, to June, 2011. 9986 (96{\%}) of 10 364 patients enrolled in the COPDGene study were included in the analysis population (mean age 59·6 years [SD 9·0]). Paradoxical response was noted in 453 (5{\%}) of 9986 patients and the frequency was similar in patients with COPD (198 [4{\%}] of 4439) and smokers without airflow obstruction (255 [5{\%}] of 5547). Compared with white patients, a paradoxical response was twice as common in African-American patients (227 [7{\%}] of 3282 vs 226 [3{\%}] of 6704; p<0·0001). In the multivariate analyses, African-American ethnic origin (adjusted odds ratio 1·89, 95{\%} CI 1·50-2·39; p<0·0001), less emphysema (0·96, 0·92-0·99; p=0·023), and increased wall-area percentage of the segmental airways (1·04, 1·01-1·08; p=0·023) were independently associated with a paradoxical response. A paradoxical response was independently associated with worse dyspnoea (adjusted β for Modified Medical Research Council Dyspnoea Scale 0·12 [95{\%} CI 0·00 to 0·24]; p=0·05), lower 6 min walk distance (-45·8 [-78·5 to -13·2]; p=0·006), higher Body Mass Index, Airflow Obstruction, Dyspnea, and Exercise Capacity (BODE) index (0·31 [0·19 to 0·43]; p<0·0001), and a greater frequency of severe exacerbations (increased by a factor of 1·35, 1·00-1·81; p=0·048). Interpretation: Paradoxical response to β2 agonists is associated with respiratory morbidity and is more common in African-Americans. These findings might have implications for the use of β2agonists in some patients. Funding: National Institutes of Health.",
author = "Bhatt, {Surya P.} and Wells, {James M.} and Victor Kim and Criner, {Gerard J.} and Hersh, {Craig P.} and Megan Hardin and Bailey, {William C.} and Hrudaya Nath and Kim, {Young il} and Foreman, {Marilyn G.} and Stinson, {Douglas S.} and Wilson, {Carla G.} and Rennard, {Stephen I.} and Silverman, {Edwin K.} and Make, {Barry J.} and Dransfield, {Mark T.}",
year = "2014",
month = "11",
day = "1",
doi = "10.1016/S2213-2600(14)70185-7",
language = "English (US)",
volume = "2",
pages = "911--918",
journal = "The Lancet Respiratory Medicine",
issn = "2213-2600",
publisher = "Elsevier Limited",
number = "11",

}

TY - JOUR

T1 - Radiological correlates and clinical implications of the paradoxical lung function response to β2 agonists

T2 - An observational study

AU - Bhatt, Surya P.

AU - Wells, James M.

AU - Kim, Victor

AU - Criner, Gerard J.

AU - Hersh, Craig P.

AU - Hardin, Megan

AU - Bailey, William C.

AU - Nath, Hrudaya

AU - Kim, Young il

AU - Foreman, Marilyn G.

AU - Stinson, Douglas S.

AU - Wilson, Carla G.

AU - Rennard, Stephen I.

AU - Silverman, Edwin K.

AU - Make, Barry J.

AU - Dransfield, Mark T.

PY - 2014/11/1

Y1 - 2014/11/1

N2 - Background: Bronchodilator response has been noted in a significant proportion of patients with chronic obstructive pulmonary disease (COPD). However, there are also reports of a paradoxical response to β2 agonists resulting in bronchoconstriction. Asymptomatic bronchoconstriction is likely to be far more common than is symptomatic bronchoconstriction with β2 agonists, but no systematic studies have been done. We assessed the prevalence of paradoxical response in current and former smokers with and without COPD, and its radiological correlates and clinical implications. Methods: Non-Hispanic white and African-American patients (aged 45-80 years) from a large multicentre study COPDGene were classified into two groups on the basis of a paradoxical response, defined as at least a 12% and 200 mL reduction in forced expiratory volume in 1 sec (FEV1) or forced vital capacity (FVC), or both, after administration of a shortacting β2 agonist (180 μg salbutamol). Findings: Patients were recruited from January, 2008, to June, 2011. 9986 (96%) of 10 364 patients enrolled in the COPDGene study were included in the analysis population (mean age 59·6 years [SD 9·0]). Paradoxical response was noted in 453 (5%) of 9986 patients and the frequency was similar in patients with COPD (198 [4%] of 4439) and smokers without airflow obstruction (255 [5%] of 5547). Compared with white patients, a paradoxical response was twice as common in African-American patients (227 [7%] of 3282 vs 226 [3%] of 6704; p<0·0001). In the multivariate analyses, African-American ethnic origin (adjusted odds ratio 1·89, 95% CI 1·50-2·39; p<0·0001), less emphysema (0·96, 0·92-0·99; p=0·023), and increased wall-area percentage of the segmental airways (1·04, 1·01-1·08; p=0·023) were independently associated with a paradoxical response. A paradoxical response was independently associated with worse dyspnoea (adjusted β for Modified Medical Research Council Dyspnoea Scale 0·12 [95% CI 0·00 to 0·24]; p=0·05), lower 6 min walk distance (-45·8 [-78·5 to -13·2]; p=0·006), higher Body Mass Index, Airflow Obstruction, Dyspnea, and Exercise Capacity (BODE) index (0·31 [0·19 to 0·43]; p<0·0001), and a greater frequency of severe exacerbations (increased by a factor of 1·35, 1·00-1·81; p=0·048). Interpretation: Paradoxical response to β2 agonists is associated with respiratory morbidity and is more common in African-Americans. These findings might have implications for the use of β2agonists in some patients. Funding: National Institutes of Health.

AB - Background: Bronchodilator response has been noted in a significant proportion of patients with chronic obstructive pulmonary disease (COPD). However, there are also reports of a paradoxical response to β2 agonists resulting in bronchoconstriction. Asymptomatic bronchoconstriction is likely to be far more common than is symptomatic bronchoconstriction with β2 agonists, but no systematic studies have been done. We assessed the prevalence of paradoxical response in current and former smokers with and without COPD, and its radiological correlates and clinical implications. Methods: Non-Hispanic white and African-American patients (aged 45-80 years) from a large multicentre study COPDGene were classified into two groups on the basis of a paradoxical response, defined as at least a 12% and 200 mL reduction in forced expiratory volume in 1 sec (FEV1) or forced vital capacity (FVC), or both, after administration of a shortacting β2 agonist (180 μg salbutamol). Findings: Patients were recruited from January, 2008, to June, 2011. 9986 (96%) of 10 364 patients enrolled in the COPDGene study were included in the analysis population (mean age 59·6 years [SD 9·0]). Paradoxical response was noted in 453 (5%) of 9986 patients and the frequency was similar in patients with COPD (198 [4%] of 4439) and smokers without airflow obstruction (255 [5%] of 5547). Compared with white patients, a paradoxical response was twice as common in African-American patients (227 [7%] of 3282 vs 226 [3%] of 6704; p<0·0001). In the multivariate analyses, African-American ethnic origin (adjusted odds ratio 1·89, 95% CI 1·50-2·39; p<0·0001), less emphysema (0·96, 0·92-0·99; p=0·023), and increased wall-area percentage of the segmental airways (1·04, 1·01-1·08; p=0·023) were independently associated with a paradoxical response. A paradoxical response was independently associated with worse dyspnoea (adjusted β for Modified Medical Research Council Dyspnoea Scale 0·12 [95% CI 0·00 to 0·24]; p=0·05), lower 6 min walk distance (-45·8 [-78·5 to -13·2]; p=0·006), higher Body Mass Index, Airflow Obstruction, Dyspnea, and Exercise Capacity (BODE) index (0·31 [0·19 to 0·43]; p<0·0001), and a greater frequency of severe exacerbations (increased by a factor of 1·35, 1·00-1·81; p=0·048). Interpretation: Paradoxical response to β2 agonists is associated with respiratory morbidity and is more common in African-Americans. These findings might have implications for the use of β2agonists in some patients. Funding: National Institutes of Health.

UR - http://www.scopus.com/inward/record.url?scp=84919329733&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84919329733&partnerID=8YFLogxK

U2 - 10.1016/S2213-2600(14)70185-7

DO - 10.1016/S2213-2600(14)70185-7

M3 - Article

C2 - 25217076

AN - SCOPUS:84919329733

VL - 2

SP - 911

EP - 918

JO - The Lancet Respiratory Medicine

JF - The Lancet Respiratory Medicine

SN - 2213-2600

IS - 11

ER -